Vicki Moore

🎄 This winter in Pacifica is packed with festive events! From holiday markets to cozy gatherings, there’s fun for all ages. Dive into the cheer! 🎅

Individualized pain plans (IPPs) to treat vaso-occlusive episodes (VOEs) were considered easy to use and elicited generally positive reactions from emergency department (ED) providers and patients with sickle cell disease (SCD) in a study. However, IPPs were not associated with a statistically significant change in patient-perceived quality (PPQ) of ED pain treatment. Study findings were reported in the journal Blood Advances.

Results from low-cost blood tests may predict chemosensitivity in pediatric classical Hodgkin lymphoma (cHL), according to a study with findings published in the journal JCO

Researchers developed a machine learning-based model for detecting paroxysmal nocturnal hemoglobinuria (PNH) based on a retrospective analysis of electronic health records. They reported their findings in the Orphanet Journal of Rare Diseases.

The use of topical chicory root extract gel appeared associated with a potential benefit in management of radiodermatitis in patients undergoing radiotherapy for breast cancer. These study findings were reported in the journal Supportive Care in Cancer.

Sitravatinib at 35 mg daily plus nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg every 3 weeks (n=7)

An analysis based in Japan identified differences in clinical characteristics between adolescents and young adults (AYA) and the non-AYA population among those with polycythemia vera (PV) or essential thrombocytopenia (ET). Findings were reported in the International Journal of Hematology.

Ipilimumab and nivolumab in the CheckMate 214 trial Atezolizumab and bevacizumab in the IMmotion151 trial Avelumab and axitinib in the JAVELIN Renal 101 trial

Relationships between the lower deformability of red blood cells (RBCs) in sickle cell disease (SCD) and processes of endothelial dysfunction were explored in a report published in the journal Blood.

A new risk prediction model for clonal cytopenia of undetermined significance (CCUS) called the Clonal Cytopenia Risk Score (CCRS) has been developed and validated in a study with results published in the journal Blood.